India’s Ranbaxy, Three Other Generics Named In Buy-Off Suit By U.S. FTC
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Pharmaceuticals of India has been named among four companies Cephalon is alleged to have paid to delay marketing a generic version of the American company's Provigil (modafinil) narcolepsy drug. The suit was filed in the U.S. District Court in Washington for the Federal Trade Commission, which said Cephalon had acted to protect a drug worth $800 million in annual sales. Besides Ranbaxy, which did not comment on the suit, other drug makers accused of providing $200 million worth of inducements were Barr Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceutical Industries. (Click here for more - a subscription may be required )
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.